Basic Trial Information
Trial Description
     Summary
     Further Trial Information
     Eligibility Criteria
Trial Contact Information

Basic Trial Information

Phase Type Status Age Sponsor Protocol IDs Phase I Treatment Active Over 18 Pharmaceutical / Industry CLTR0305-101 NCT00389428

Trial Description

Summary

The primary objective of this study is to determine the recommended dose of CPX-351 for use in a phase 2 efficacy study in patients with leukemia. Secondarily, the study will assess the safety, serious adverse effects and how the body handles CPX-351. Preliminary evidence of antitumor activity will also be determined.

Further Study Information

CPX-351 is a liposomal formulation of a fixed combination of the antineoplastic drugs cytarabine and daunorubicin. The two drugs are present inside the liposome in a 5:1 molar ratio. The development of CPX-351 (cytarabine:daunorubicin) Liposome Injection was based on 1) defining a synergistic ratio of the two active moieties, cytarabine and daunorubicin, using cell-based screening assays and 2) designing a liposomal drug carrier to maintain this ratio after intravenous administration. CPX-351 was found to be more active in in vivo models of cancer than combinations of conventional cytarabine and daunorubicin. Both cytarabine and daunorubicin are active chemotherapeutic agents, each approved for clinical use in the United States for the treatment of hematological neoplasms.

CPX-351 is being developed with the hypothesis that it is superior to the currently used regimen of cytarabine and daunorubicin in the treatment of acute leukemia. This phase I study will determine the dose to carry forward into phase II trials.

Eligibility Criteria

Inclusion Criteria:

• Ability to understand and voluntarily sign an informed consent form

• Age > 18 years at the time of signing the informed consent form

• Pathological confirmation of leukemia or myelodysplastic syndrome.

• AML according to WHO criteria; except for core-binding factor AMLs (t(8;21), inv(16) or t(16;16)) and APL

• ALL

• MDS

• Patients with AML include the following:

• Patients in 2nd or greater relapse

• Patients in first relapse with initial CR duration lasting <6 months

• Patients in first relapse refractory to induction therapy

• Patients with primary refractory AML

• Patients with ALL include the following

• Patients with T-cell ALL refractory or in relapse following nelarabine

• Patients with other ALL that is refractory or in relapse.

• Patients with MDS include the following:

• The subset of RAEB-2 patients with >10% blasts with at least 1 prior therapy that includes a hypomethylating agent.

• Previously untreated chemotherapy induced AML

• Eastern Cooperative Oncology Group (ECOG) performance status score of 0,1 or 2

• Able to adhere to the study visit schedule and other protocol requirements

• Life expectancy of at least 12 weeks

• Laboratory values fulfilling the following:

• Serum creatinine < 1.5 mg/dL

• Serum total bilirubin < 1.5 mg/dL

• Serum alanine aminotransferase or aspartate aminotransferase < 150 IU/liter Note: If elevated liver enzymes are related to disease; contact medical monitor to discuss.

• Cardiac ejection fraction > 50% by MUGA scan or echocardiography

• All men and women must agree to practice effective contraception during the study period if not otherwise documented to be infertile.

Exclusion Criteria:

• Any serious medical condition, laboratory abnormality or psychiatric illness that would prevent the patient from signing the informed consent form

• Chemotherapy or other investigational anticancer therapeutic drugs in the two weeks prior to study entry; in the event of rapidly proliferative disease, however, the use of hydroxyurea is permitted up to 24 hours before study entry

• Clinical evidence of active CNS leukemic involvement

• Pregnant or lactating women

• Clinically significant cardiac disease (New York Heart Association Class III or IV)

• Severe debilitating pulmonary disease

• Active and uncontrolled infection. Patients with an infection under active treatment with antibiotics and whose infection is controlled may be entered into the study

• Current evidence of invasive fungal infection (blood or tissue culture); HIV or hepatitis C infection

• Hypersensitivity to cytarabine, daunorubicin or liposomal products

• History of Wilson's disease or other copper-related disorder

Trial Contact Information

Trial Lead Organizations/Sponsors

Celator Pharmaceuticals, Incorporated

Arthur Louie, M.D.

Study Director

Jonathan Kolitz, M.D.

Principal Investigator

Michael Chiarella		Ph: 609-243-0123
		Email: mchiarella@celatorpharma.com

Arthur Louie, M.D.		Ph: 609-243-0123
		Email: alouie@celatorpharma.com

U.S.A.
District of Columbia
	Washington
	Lombardi Comprehensive Cancer Center at Georgetown University Medical Center
		Pari Ramzi	Ph: 202-784-0038
			Email: ramzip1@georgetown.edu
		Ekatherine Asatiani, MD	Principal Investigator
Florida
	Tampa
	H. Lee Moffitt Cancer Center and Research Institute at University of South Florida
		Michelle K Burton, RN, BSN	Ph: 813-979-3965
			Email: BurtonMK@moffitt.usf.edu
		Jeffrey E. Lancet	Principal Investigator
New York
	Manhasset
	Don Monti Comprehensive Cancer Center at North Shore University Hospital
		Marjorie Fricano, RN,BSN,OSN	Ph: 516-734-8942
			Email: mfricano@nshs.edu
		Jonathan Eliahu Kolitz	Principal Investigator
	New York
	New York Weill Cornell Cancer Center at Cornell University
		Tania Curcio, RN,BSN,CCRC	Ph: 212-746-2571
			Email: tjc9003@med.cornell.edu
		Eric Feldman, M.D.	Principal Investigator

Link to the current ClinicalTrials.gov record.
NLM Identifer NCT00389428
Information obtained from ClinicalTrials.gov on May 27, 2008